Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-08
2006-08-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S273000, C544S320000, C544S321000, C540S524000
Reexamination Certificate
active
07087597
ABSTRACT:
Compounds of the formulawherein R1, R2, R3, R4, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.
REFERENCES:
patent: 4959368 (1990-09-01), Awaya et al.
patent: 6432963 (2002-08-01), Hisamichi et al.
patent: 19636487 (1998-03-01), None
patent: 0012361 (1980-06-01), None
patent: 0188094 (1986-07-01), None
patent: 0557877 (1993-09-01), None
patent: 0557879 (1993-09-01), None
patent: 0640599 (1995-03-01), None
patent: 0816358 (1998-01-01), None
patent: 0816359 (1998-01-01), None
patent: 1054004 (2000-11-01), None
patent: 901749 (1962-07-01), None
patent: 933159 (1963-08-01), None
patent: 61087672 (1986-05-01), None
patent: WO 99/06046 (1999-02-01), None
patent: WO 99/31073 (1999-06-01), None
Damasio, Alzheimer's Disease, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Jacob et al., PubMed Abstract (Therapie 57(2):163-8), 2002.
Rosen et al., PubMed Abstract (Annu Rev Sex Res 13:36-88), 2002.
Torphy, Phosphodiesterase Isozymes, Am J Respir Crit Care Med. vol. 157, pp. 351-370, 1998.
Reffelmann et al., Therapeutic Potential of Phsophodiesterase 5 Inhibition for Cardiovascular Disease, Circulation, pp. 239-244, 2003 (www.circulationaha.org).
Maurice et al., Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System, Molecular Pharmacology, vol. 64, No. 3, pp. 533-546, 2003.
Taylor, et al. “Heterocyclic Compounds” Chemical Abstracts 55:Columns 6489 and 6491 (1961).
Xiang, et al. “Synthesis and Biological Examination of New Pyrimidine Type Derivatives as Potential Phosphodiesterase(PDE) V Inhibitors” Korean J. of Med. Chem 8: 6-9(1998) No. 1.
Doi Takayuki
Miwa Tetsuo
Tarui Naoki
Yamamoto Mitsuo
Chao Mark
Ramesh Elaine M.
Rao Deepak
Takeda Pharmaceutical Company Limited
LandOfFree
Pyrimidine 5-carboxamide compounds, process for producing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine 5-carboxamide compounds, process for producing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine 5-carboxamide compounds, process for producing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643953